Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.
Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.
Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.
